Does Medicaid Pay Too Much for Prescription Drugs? A Case Study of Atypical Anti-Psychotics
AbstractDuring the last several years, government spending on drugs used to treat schizophrenia and other psychotic illnesses has increased at more than 30% per year, with the $3 billion in 2001 Medicaid expenditures exceeding spending in any other therapeutic category. This growth has been primarily driven by a shift to atypical anti-psychotic drugs, which are several times more expensive than the conventional anti-psychotics that preceded them and are purchased almost exclusively by state governments through the Medicaid program. In this paper, I estimate the productivity of these new drugs using a 5% sample of California Medicaid recipients eligible for the program in at least one month between January of 1993 and December of 2001 and diagnosed with schizophrenia during that period. My results indicate that the shift to atypical anti-psychotics has significantly increased government spending, has not reduced the utilization of hospitals or long-term care facilities, and has not improved observable measures of health among Medicaid recipients. The findings suggest that the price of a prescription drug purchased differentially by consumers with Medicaid or other public health insurance may be an inaccurate measure of it value to patients.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by National Bureau of Economic Research, Inc in its series NBER Working Papers with number 9626.
Date of creation: Apr 2003
Date of revision:
Publication status: published as Duggan, Mark. "Do New Prescription Drugs Pay For Themselves?: The Case Of Second-Generation Antipsychotic," Journal of Health Economics, 2005, v24(1,Jan), 1-31.
Contact details of provider:
Postal: National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.
Web page: http://www.nber.org
More information through EDIRC
Find related papers by JEL classification:
- H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
- H57 - Public Economics - - National Government Expenditures and Related Policies - - - Procurement
This paper has been announced in the following NEP Reports:
- NEP-ALL-2003-04-21 (All new papers)
- NEP-HEA-2003-04-21 (Health Economics)
- NEP-IAS-2003-04-21 (Insurance Economics)
- NEP-LAB-2003-04-21 (Labour Economics)
- NEP-MAC-2003-04-21 (Macroeconomics)
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- David H. Autor & Mark G. Duggan, 2003. "The Rise In The Disability Rolls And The Decline In Unemployment," The Quarterly Journal of Economics, MIT Press, MIT Press, vol. 118(1), pages 157-205, February.
- Berndt, Ernst R. & Finkelstein, Stan N. & Greenberg, Paul E. & Howland, Robert H. & Keith, Alison & Rush, A. John & Russell, James & Keller, Martin B., 1998. "Workplace performance effects from chronic depression and its treatment," Journal of Health Economics, Elsevier, vol. 17(5), pages 511-535, October.
- Mark Duggan, 2002.
"Does Contracting Out Increase the Efficiency of Government Programs? Evidence from Medicaid HMOs,"
NBER Working Papers
9091, National Bureau of Economic Research, Inc.
- Duggan, Mark, 2004. "Does contracting out increase the efficiency of government programs? Evidence from Medicaid HMOs," Journal of Public Economics, Elsevier, vol. 88(12), pages 2549-2572, December.
- Duggan, Mark, 2005. "Do new prescription drugs pay for themselves?: The case of second-generation antipsychotics," Journal of Health Economics, Elsevier, vol. 24(1), pages 1-31, January.
- Frank, Richard G. & Berndt, Ernst R. & Busch, Alisa B. & Lehman, Anthony F., 2004. "Quality-constant "prices" for the ongoing treatment of schizophrenia: an exploratory study," The Quarterly Review of Economics and Finance, Elsevier, Elsevier, vol. 44(3), pages 390-409, July.
- Richard G. Frank & Ernst R. Berndt & Alisa B. Busch, 2003. "Quality-Constant Price Indexes for the Ongoing Treatment of Schizophrenia: An Exploratory Study," NBER Working Papers 10022, National Bureau of Economic Research, Inc.
- Nasreen Khan & Robert Kaestner & Swu Jane Lin, 2007. "Prescription Drug Insurance and Its Effect on Utilization and Health of the Elderly," NBER Working Papers 12848, National Bureau of Economic Research, Inc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().
If references are entirely missing, you can add them using this form.